Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Lipids ; 50(11): 1133-43, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26395388

ABSTRACT

The effects of supplementing diets with n-3 alpha-linolenic acid (ALA) and docosahexaenoic acid (DHA) on plasma metabolites, carcass yield, muscle n-3 fatty acids and liver messenger RNA (mRNA) in lambs were investigated. Lambs (n = 120) were stratified to 12 groups based on body weight (35 ± 3.1 kg), and within groups randomly allocated to four dietary treatments: basal diet (BAS), BAS with 10.7 % flaxseed supplement (Flax), BAS with 1.8 % algae supplement (DHA), BAS with Flax and DHA (FlaxDHA). Lambs were fed for 56 days. Blood samples were collected on day 0 and day 56, and plasma analysed for insulin and lipids. Lambs were slaughtered, and carcass traits measured. At 30 min and 24 h, liver and muscle samples, respectively, were collected for determination of mRNA (FADS1, FADS2, CPT1A, ACOX1) and fatty acid composition. Lambs fed Flax had higher plasma triacylglycerol, body weight, body fat and carcass yield compared with the BAS group (P < 0.001). DHA supplementation increased carcass yield and muscle DHA while lowering plasma insulin compared with the BAS diet (P < 0.01). Flax treatment increased (P < 0.001) muscle ALA concentration, while DHA treatment increased (P < 0.001) muscle DHA concentration. Liver mRNA FADS2 was higher and CPT1A lower in the DHA group (P < 0.05). The FlaxDHA diet had additive effects, including higher FADS1 and ACOX1 mRNA than for the Flax or DHA diet. In summary, supplementation with ALA or DHA modulated plasma metabolites, muscle DHA, body fat and liver gene expression differently.


Subject(s)
Adipose Tissue/metabolism , Fatty Acids, Omega-3/metabolism , Liver/metabolism , RNA, Messenger/biosynthesis , Acyl-CoA Oxidase/biosynthesis , Animal Feed , Animals , Carnitine O-Palmitoyltransferase/biosynthesis , Dietary Supplements , Docosahexaenoic Acids/administration & dosage , Fatty Acid Desaturases/biosynthesis , Muscle, Skeletal/metabolism , Sheep, Domestic , alpha-Linolenic Acid/administration & dosage
2.
Life Sci ; 82(15-16): 876-83, 2008 Apr 09.
Article in English | MEDLINE | ID: mdl-18374364

ABSTRACT

The experiments performed in this report were designed to investigate the mechanisms involved in the metabolic alterations associated with orotic acid-induced hepatic steatosis and the effect of fenofibrate, a stimulant of peroxisome proliferators-activated receptor alpha (PPARalpha), on these alterations. Male Wistar rats were divided into three experimental groups: 1) fed a balanced diet (C); 2) fed a balanced diet supplemented with 1% orotic acid (OA); 3) fed OA diet containing 100 mg.kg(-1) bw.day(-1) fenofibrate (OA+F), for 9 days. Administration of OA to rats induced significant increase in the hepatic total lipids content, marked microvesicular steatosis and decrease in plasma lipids concentrations compared to control group. Fenofibrate treatment prevented fatty liver induction, caused an additional reduction on plasma lipids concentrations and caused a 40% decrease in the lipogenic rate in adipose tissue. The results also showed a 40% increase in lipoprotein lipase (LPL) activity in adipose tissue from OA treated group and fenofibrate administration induced a 50% decrease in LPL activity. The liver mRNA expression of PPARalpha and ACO (acyl CoA oxidase) were 85% and 68% decreased in OA group when compared to control, respectively. Fenofibrate treatment increased the PPARalpha and ACO expressions whereas the CPT-1 (carnitine palmitoyl transferase-1) expression was not altered. Our results have shown that fenofibrate treatment decreases the hepatic lipid content induced by OA which is mediated by an important increase in fatty acid oxidation consequent to an increase in hepatic mRNA expression of PPARalpha and ACO.


Subject(s)
Fenofibrate/therapeutic use , Hepatic Insufficiency/chemically induced , Hepatic Insufficiency/prevention & control , Hypolipidemic Agents/therapeutic use , Orotic Acid/antagonists & inhibitors , Orotic Acid/toxicity , Acyl-CoA Oxidase/biosynthesis , Adipocytes/drug effects , Adipocytes/metabolism , Adrenergic beta-Agonists/pharmacology , Animals , Cell Separation , Diet , Hepatic Insufficiency/pathology , Hypoglycemic Agents/pharmacology , Insulin/pharmacology , Isoproterenol/pharmacology , Lipid Metabolism/drug effects , Lipids/biosynthesis , Lipolysis/drug effects , Lipoprotein Lipase/metabolism , Liver/pathology , Male , PPAR alpha/biosynthesis , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL